Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children
Brief Summary: The main objective is to compare the safety and efficacy of 4 artemisinin-based combinations (ACT) \[amodiaquine-artesunate (AQ+AS), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL) and chlorproguanil/dapsone plus artesunate\] for single and repeat treatments of uncomplicated malaria in children. Safety will be determined by registering adverse events and grading, laboratory, and vital signs evaluations. Their incidence will be compared between the different study arms.

TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities. The leading EC approved the amendment on 2nd June 2008.

TO BE NOTED: since the batches of the study drug DHAPQ expire at the end of October 2008, and because of the unavailability of a new batch of DHAPQ from the manufacturer, the recruitment in the DHAPQ arm had to be discontinued on 30th October 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amodiaquine-artesunate (ASAQ) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: dihydroartemisinin-piperaquine (DHAPQ) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: artemether-lumefantrine (AL) | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS) | Intervention Type: DRUG; Name: amodiaquine-artesunate (ASAQ); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine (DHAPQ); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: artemether-lumefantrine (AL); Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS); Assigned to Arm(s): 4
B: Arm Label: Dihydroartemisin-piperaquine; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisin-piperaquine | Arm Label: Mefloquine + Artesunate (MAS3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine + Artesunate | Intervention Type: DRUG; Name: Dihydroartemisin-piperaquine; Assigned to Arm(s): Dihydroartemisin-piperaquine | Intervention Type: DRUG; Name: Mefloquine + Artesunate; Assigned to Arm(s): Mefloquine + Artesunate (MAS3)
C: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A
D: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine

Answer: A